Lowell B. Anthony, MD, FACP
Lowell B. Anthony, MD, FACP
- Chief, Division of Medical Oncology
Conditions
About
Lowell Anthony joined the UK Markey Cancer Center with more than two decades of experience in oncology and a special focus in gastrointestinal and neuroendocrine oncology. His clinical interests include drug development ranging from Phase I to III clinical trials. Agents targeting specific cellular signaling pathways and injectable radiolabeled compounds make up his past and current clinical investigative interests. He brings a clinical correlative component to complement the ongoing translational activities at Markey Cancer Center.
Dr. Anthony attended Vanderbilt University Medical School, where he also completed a medical residency and fellowship training in medical oncology and clinical pharmacology. He has previously been on the medical faculties at Vanderbilt University and the Louisiana State University Health Sciences Center in New Orleans.
Personal Statement
It takes a village to treat cancer, so when the patient is initially evaluated at Markey Cancer Center, a care plan is developed across specialties. So it's more encompassing than just a single visit to one specialist who treats cancer. Right now in oncology, the most exciting development is immunotherapy. Our challenge is to find out how we integrate this into other forms of how we treat cancer; both from other medicine, other drugs and potentially other modalities such as radiation.
Faculty Rank
- Professor of Medicine
- fixes empty view field issue
Training & Education
Degree
Residency
Fellowship
Certifications and Special Training
Research
Research Focus
Neuroendocrine cancer, gastrointestinal malignancies.
Programs
Translational OncologyCollege & Department
Contact Information
800 Rose Street
CC454 Roach Building, University of Kentucky
Lexington, KY 40536
United States
Publications
- Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.J Surg Oncol. 2016 May 30. Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CD.
View Publication - Unexpected Cardiac Masses.JAMA Oncol. 2015 Dec;1(9):1343-4. Hilal T, Anthony LB, Sorrell VL.
View Publication - Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.Neuroendocrinology. 2015;102(1-2):18-25.Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC.
View Publication - Practical guide to supportive care of patients with functional neuroendocrine tumors.Semin Oncol. 2013 Feb; 40(1):45-55. PMID: 23391112. Anthony LB.
View Publication - Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study.Oncologist. 2013; 18(1):46-53. PMID: 23263288. Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T.
View Publication